OBJECTIVE： To investigate the differences of antibacterial agent products directory between China and America， and to provide reference for the relevant departments. METHODS： Using domestic and imported drug data released by China Food and Drug Administration （CFDA） and national drug code （NDC） issued by America Food and Drug Administration （FDA）， antibacterial drugs of China and America were analyzed comparatively in respects of types， specification， the number of products， child-size dosage form， concentration ratio of manufacturers. RESULTS & CONCLUSIONS： In CFDA’s and FDA’s directory of antibacterial drugs， the number of type， specification and product were 191 and 84， 460 and 1 392， 23 824 and 3 139， respectively. The number of child-size dosage form were 51 and 26. The number of products in enterprises with the top 10 product number accounted for 6.29％ and 33.67％. In China， the type and specification of antibacterial drugs are abundant but low. It is recommend that antibacterial drugs’ approval should be examined and supervised strictly. At the same time， products already marketed should be reselected and revaluated， and price or market mechanism should be adopted to promote the survival of the fittest of antibacterial drugs.